Q-omics provides the consensus-scored VTRNA1-2 profile across patient tissues and cancer cell-line models. VTRNA1-2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VTRNA1-2 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, VTRNA1-2 RNA expression shows 6,176 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where VTRNA1-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VTRNA1-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VTRNA1-2 survival associations across molecular data types. VTRNA1-2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VTRNA1-2 RNA expression–survival associations across cancer types. High VTRNA1-2 expression shows unfavorable associations in KIRC, MESO, THYM, LGG and LUAD, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VTRNA1-2 RNA expression.
This table summarizes VTRNA1-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for VTRNA1-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VTRNA1-2 shows lower tumor expression in COAD and higher tumor expression in KIRC, LUAD, LIHC and UCEC. The KIRC box plot shows higher VTRNA1-2 RNA expression in tumor versus normal tissue (log2 FC = +0.270, t-test p < 0.001).
This table shows molecular features associated with VTRNA1-2 in patient tissues and cancer cell lines. In patient samples, VTRNA1-2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
